M B Toft-Nielsen
Overview
Explore the profile of M B Toft-Nielsen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
418
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Svane M, Toft-Nielsen M, Kristiansen V, Hartmann B, Holst J, Madsbad S, et al.
Diabet Med
. 2017 Aug;
34(12):1783-1787.
PMID: 28782840
Background: Roux-en-Y gastric bypass is associated with an increased risk of postprandial hyperinsulinaemic hypoglycaemia, but the underlying pathophysiology remains poorly understood. We therefore examined the effect of re-routing of nutrient...
2.
Toft-Nielsen M, Madsbad S, Holst J
J Clin Endocrinol Metab
. 2001 Aug;
86(8):3853-60.
PMID: 11502823
GLP-1 lowers blood glucose in fasting type 2 diabetic patients. To clarify the relation of the effect of GLP-1 to obesity, blood glucose, beta-cell function, and insulin sensitivity, GLP-1 (1.2...
3.
Toft-Nielsen M, Damholt M, Madsbad S, Hilsted L, Hughes T, Michelsen B, et al.
J Clin Endocrinol Metab
. 2001 Aug;
86(8):3717-23.
PMID: 11502801
To elucidate the causes of the diminished incretin effect in type 2 diabetes mellitus we investigated the secretion of the incretin hormones, glucagon-like peptide-1 and glucose- dependent insulinotropic polypeptide and...
4.
Zander M, Taskiran M, Toft-Nielsen M, Madsbad S, Holst J
Diabetes Care
. 2001 Apr;
24(4):720-5.
PMID: 11315837
Objective: The incretin hormone glucagon-like peptide-1 (GLP-1) reduces plasma glucose in type 2 diabetic patients by stimulating insulin secretion and inhibiting glucagon secretion. The biguanide metformin is believed to lower...
5.
Vilsboll T, Toft-Nielsen M, Krarup T, Madsbad S, Dinesen B, Holst J
Diabetes Care
. 2000 Jun;
23(6):807-12.
PMID: 10841001
Objective: Beta-cell secretory capacity is often evaluated with a glucagon test or a meal test. However, glucagon-like peptide 1 (GLP-1) is the most insulinotropic hormone known, and the effect is...
6.
Toft-Nielsen M, Madsbad S, Holst J
Diabetes Care
. 1999 Jul;
22(7):1137-43.
PMID: 10388979
Objective: The gut hormone glucagon-like peptide 1 (GLP-1) has insulinotropic and anorectic effects during intravenous infusion and has been proposed as a new treatment for type 2 diabetes and obesity....
7.
Holst J, Deacon C, Toft-Nielsen M
Ann N Y Acad Sci
. 1999 Feb;
865:336-43.
PMID: 9928027
As a therapeutic principle, the insulinotropic peptide, GLP-1, of the secretin-glucagon family of peptides, has turned out to possess some remarkably attractive properties, including the capability of normalizing blood glucose...
8.
Holst J, Toft-Nielsen M, Orskov C, Nauck M, Willms B
Ann N Y Acad Sci
. 1996 Dec;
805:729-36.
PMID: 8993469
No abstract available.